Meaney E, Gutiérrez-Salmeán G, Fanghaënel G, Sánchez L, Nájera N, Rivera JM, Alcocer A, Ceballos G

Language: English
References: 43
Page: 154-162
PDF size: 216.17 Kb.

Text Extraction

In the first part of this text we described some stellar moments of the dystocic birth and twisting evolution of the condition known as the metabolic syndrome (MS), signaling, by the way, the myriad of terms used to name it. In this regard, to begin with, when a condition brings together so many names, something is wrong in both conception and/ or perception of the underlying phenomenon. The costly epidemiological importance of the MS requires a frontal combat on the part of medical profession and all the State organs, the executive actions of health agencies, as well as the resolute collaboration of the entire society. As in all battles, in order to set up proper immediate tactics and successful long-term strategies, a clear operational definition and a sharp profile of the enemy is a basic and decisive requirement. It is always desirable, that the name given to the condition we are fighting must be a faithful reflection of its true nature.

REFERENCES

1. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Stat Health Report. 2009; 13: 1-7.

2. Bianci C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E et al. Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutr Metab Cardiovasc Dis. 2011; 21 (9): 699-705.

3. Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D et al. Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health. 2010; 10: 529.

4. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A et al. High prevalence of metabolic syndrome in Mexico. Arch Med Res. 2004; 35: 76-81.

5. Available in: http://www.dictionary.com/browse/disease

6. Velázquez Moreno H, Gaxiola Cáceres S, Alcocer Chauvet A, González Coronado, VJ, Zárate Chavarría E, Meaney E. Obesidad y síndrome metabólico. En Medicina Cardiovascular. Asociación Nacional de Cardiólogos de México. Masson Doyma México, S.A. México, D.F. 2012, p. 124.

7. Gierach M, Spychalska M, Junik R. Insulin resistance as a disease of civilization. Med & Biol Sci. 2013; 27 (4): 17-22.

8. Vinik A, Bell G. Mutant insulin syndromes. Horm Metab Res. 1988; 20 (1): 1-10.

9. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014; 6 (1): a009191.

10. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension. 2005; 45 (5): 828-833.

11. Tritos NA, Mantzoros CS. Syndromes of severe insulin resistance. JCE & M. 1998; 83 (9): 3025-3030.

12. Hussain I, Garg A. Lipodystrophy syndromes. Dermatol Clin. 2008; 26 (4): 569-ix.

13. Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs. 1999; 58 (Suppl 1): 7-10.

14. Aronis KN, Mantzoros CS. A brief history of insulin resistance: from the first insulin radioimmunoassay to selectively targeting protein kinase C pathways. Metabolism. 2012; 61 (4): 445-449.

15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120 (16): 1640-1645.

16. Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366 (9491): 1059-1062.

17. Available in: http://medical-dictionary.thefreedictionary.com/Metabolism.

18. Grundy SM, Brewer B Jr, Cleeman JI, Smith SC Jr, Lenfant C et al. Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004; 109 (3): 433-438.

19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112 (17): 2735-2752.

20. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004; 89 (6): 2595-2600.

21. Grundy SM. The metabolic syndrome still lives. Clin Chem. 2005; 51 (18): 1352-1354.

22. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N Engl J Med. 1987; 317 (6): 350-357.

23. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension. 1997; 30 (5): 1144-1149.

24. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996; 334 (6): 374-381.

25. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S et al. Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension. 2004; 43 (6): 1324-1331.

26. Dong Z, Huang J, Huang L, Chen X, Yin Q, Yang D. Associations of Acanthosis nigricans with metabolic abnormalities in polycystic ovary syndrome women with normal body mass index. J Dermatol. 2013; 40 (3): 188-192.

27. Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metabol. 1992; 75 (2): 508-513.

28. Hearst MO, Laska NM, Himes JH, Butterbrodt M, Sinaiko A, Cloud RI et al. The co-occurrence of obesity, elevated blood pressure and acanthosis nigricans among American Indian school-children: Identifying individual heritage and environment-level correlates. Am J Hum Biol. 2011; 23 (3): 346-352.

29. Kronenberg F; Rich S, Sholinsky P, Arnett DK, Province ME, Myers RH et al. Insulin and hypertension in the NHLBI family heart study: a sib pair approach to a controversial issue. Am J Hypertens. 2000; 13: 240-250.

30. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004; 17 (10): 904-910.

31. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX et al. Obesity and cardiovascular disease. Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006; 26 (5): 968-976.

32. Brown CD, Higgins M, Donato KA, Rhode FC, Garrison R, Obarsanek E et al. Body Mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000; 8 (9): 605-619.

33. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011; 95 (5): 875-892.

34. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012; 19 (2): 81-87.

35. García-Estévez DA, Araújo-Vilar D, Saavedra-González Á, Fiestras-Janeiro G, Cabezas-Cerrato J. Analysis of the relationship between body mass index, insulin resistance, and beta-cell function: A cross-sectional study using the minimal model. Metabolism. 2004; 53 (11): 1462-1466.

36. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015; 116 (6): 991-1006.

37. Fanghänel-Salmón G, Gutiérrez-Salmeán G, Samaniego V, Meaney A, Sánchez-Reyes L, Navarrete U et al. Obesity phenotypes in urban middle-class cohorts; the prit-lindavista merging evidence in Mexico: The OPUS PRIME study. Nutr Hosp. 2015; 32 (1): 182-188.

38. Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza-Tobías A, Rivera-Dommarco J. Prevalencia de obesidad en adultos mexicanos, ENSANUT 2012. Salud Publica Mex. 2013; 55 (Supl 2): S151-S160.

39. Pajunen P, Kotronen A, Korpi-Hyövälti E, Keinänen-Kiukaanniemi S, Oksa H, Niskanen L et al. Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D Survey. BMC Public Health. 2011; 11: 754.

40. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008; 168 (15): 1617-1624.

41. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013; 159 (11): 758-769.

42. Stagnaro S. Biophysical-semeiotic pre-metabolic syndrome, metabolic syndrome, type 2 diabetes mellitus, and depression. BMJ. 2003; 327: 1383.

43. Vidigal FC, Ribeiro AQ, Babio N, Salas-Salvadó J, Bressanet J. Prevalence of metabolic syndrome and pre-metabolic syndrome in health professionals: LATINMETS Brazil study. Diabetol Metab Syndr. 2015; 7: 6.